Grufity logoGrufity logo

ADAP

2.05USD+0.03(+1.49%)Delayedas of 02 Dec 2022, 12:00 pm

Adaptimmune Therapeutics PLC

Market Summary

USD2.05+0.03Delayedas of 02 Dec 2022, 12:00 pm
1.49%

ADAP Stock Price

RSI Chart

Valuation

Market Cap

1.4B

Price/Earnings

-7.71

Price/Sales

115.72

Price/Cashflow

-196.09

MarketCap/EBT

-7.78

Price/Sales

Profitability

EBT Margin

-1487.45%

Return on Equity

-124.05%

Return on Assets

-45.34%

Fundamentals

Revenue

Revenue (TTM)

17.5M

Revenue Y/Y

482.46%

Revenue Q/Q

26.53%

Earnings

Earnings (TTM)

-175.1M

Earnings Y/Y

2.31%

Earnings Q/Q

6.96%

Price Action

52 Week Range

1.014.17
(Low)(High)

Last 7 days

-9.4%

Last 30 days

39.3%

Trailing 12 Months

-45.4%

Financial Health

Current Ratio

4.36

Investor Care

Shares Dilution (1Y)

4.87%

Diluted EPS (TTM)

-0.18

Peers (Alternatives to Adaptimmune Therapeutics)

View All Peers In Detail
NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
146.5B
26.3B
5.83% 46.90%
22.27
5.55
2.18% 21.86%
99.4B
27.1B
10.79% 33.59%
24.02
3.61
-1.26% -54.91%
59.1B
23.0B
17.37% -41.57%
4.2
2.57
227.55% 302.16%
41.3B
10.4B
7.79% 31.53%
14.4
3.98
-6.64% 85.32%
11.1B
1.4B
5.82% 56.34%
905.99
8.52
29.86% -86.92%
MID-CAP
3.7B
112.4M
7.73% -29.76%
-12.87
32.5
-41.50% -607.58%
3.4B
-
3.31% -36.94%
-14.65
59.51
215916.67% 21.41%
2.1B
68.3M
-3.10% -60.98%
-8.33
30.98
42.18% -19.70%
2.0B
432.8M
38.23% -20.10%
29.99
4.9
1042.97% 128.67%
SMALL-CAP
1.8B
1.8B
-23.41% -91.25%
-1.22
1.39
53.41% -22.97%
1.6B
69.7M
-11.59% -76.67%
-3.15
20.84
745.14% -7.72%
891.0M
3.2M
4.83% -28.67%
-6.7
275.59
11.14% -46.59%
692.0M
114.2M
-18.91% -55.56%
-4.02
6.06
-17.11% -27.41%
458.1M
-
-22.33% -91.55%
-13.56
44.06
522.71% -129.91%
218.9M
-
-27.78% -83.37%
-2.36
609.63
-71.03% -64.56%

Financials for Adaptimmune Therapeutics

Income Statement (Last 12 Months)
(In Thousands)
Description(%) Q/Q2022Q32022Q22022Q12021Q42021Q3
Revenue49.5%17,53711,7339,2906,1496,234
  S&GA Expenses2.7%62,94561,30360,29257,30555,767
  R&D Expenses3.8%134,179129,208123,336111,090107,362
Earnings Before Taxes0.7%-173,352.00-174,523.00-169,465.00-157,299.00-155,211.00
Net Income0.6%-175,064.00-176,044.00-170,592.00-158,090.00-155,845.00
Balance Sheet
(In Millions)
Description(%) Q/Q2022Q32022Q22022Q12021Q42021Q3
Assets-14.4%332388420470354
  Current Assets-17.8%264321359415300
    Cash Equivalents-19.2%79989015043
  Net PPE6.1%4845373029
Liabilities-11.2%219246257264113
  Current Liabilities-10.3%6674666341
Shareholder's Equity-20.1%113142163206241
  Retained Earnings-4.9%-880.05-838.63-794.11-743.85-704.99
  Additional Paid-In Capital0.5%985980965960955
Accumulated Depreciation-2.3%3536373635
Shares Outstanding0.6%983977941938937
Cashflow (Last 12 Months)
(In Millions)
Description(%) Q/Q2022Q32022Q22022Q12021Q42021Q3
Cashflow From Operations-42.7%-9.88-6.92311-152.41
  Share Based Compensation-6.6%1920212119
Cashflow From Investing-13.1%40464976112
Cashflow From Financing12.9%1210333

Risks

What is the probability of a big loss on ADAP?

100%


Probability that Adaptimmune Therapeutics stock will be more than 20% underwater in next one year

88.1%


Probability that Adaptimmune Therapeutics stock will be more than 30% underwater in next one year.

83.5%


Probability that Adaptimmune Therapeutics stock will be more than 40% underwater in next one year.
*Calculated based on probability distribution of losses observed in actual data in the last 5 years.

How does ADAP drawdown profile look like?

Y-axis is the maximum loss one would have experienced if Adaptimmune Therapeutics was unfortunately bought at previous high price.

Returns

Cumulative Returns on ADAP

-20.8%


7-Year Cumulative Returns

-24.2%


5-Year Cumulative Returns

19.3%


3-Year Cumulative Returns

What are the long-term rolling returns for ADAP?

FIve years rolling returns for Adaptimmune Therapeutics.

Which funds bought or sold ADAP recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
2022-11-16
CAPTRUST FINANCIAL ADVISORS
ADDED
324.53
13,000
21,000
-%
2022-11-15
STATE STREET CORP
REDUCED
-15.61
-291,000
332,000
-%
2022-11-15
Clearstead Advisors, LLC
UNCHANGED
-
-
1,000
-%
2022-11-15
HARBOUR INVESTMENTS, INC.
UNCHANGED
-
-
-
-%
2022-11-15
CONCOURSE FINANCIAL GROUP SECURITIES, INC.
SOLD OFF
-
-
-
-%
2022-11-15
JANE STREET GROUP, LLC
SOLD OFF
-100
-75,000
-
-%
2022-11-15
BNP PARIBAS ARBITRAGE, SNC
REDUCED
-79.83
-3,102
454
-%
2022-11-14
BAKER BROS. ADVISORS LP
UNCHANGED
-
-6,144,000
10,568,000
0.07%
2022-11-14
MILLENNIUM MANAGEMENT LLC
REDUCED
-90.66
-196,000
12,000
-%
2022-11-14
GSA CAPITAL PARTNERS LLP
NEW
-
410,000
410,000
0.05%

1–10 of 47

Latest Funds Activity

Are funds buying ADAP calls or puts?
Are funds bullish or bearish(Calls - Puts)?
No. of funds that own ADAP

Adaptimmune Therapeutics News

ETF Daily News

Adaptimmune Therapeutics (NASDAQ:ADAP) Stock Crosses Above 50-Day Moving Average of $1.62.8 hours ago

ADAP Fair Value

Recent SEC filings of Adaptimmune Therapeutics

View All Filings
Date Filed Form Type Document
Nov 08, 2022
8-K
Current Report
Nov 08, 2022
8-K
Current Report
Nov 08, 2022
10-Q
Quarterly Report
Oct 25, 2022
8-K
Current Report
Sep 09, 2022
8-K
Current Report
Sep 01, 2022
4
Insider Trading

Latest Insider Trading transactions for ADAP

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
2022-09-01
Rawcliffe Adrian
SOLD
-4,993.13
1.9689
-2,536
Chief Executive Officer
2022-08-01
Piccina Cintia
SOLD
-37,314.4
1.7735
-21,040
Chief Commercial Officer
2022-08-01
Lunger John
SOLD
-5,290.35
1.7735
-2,983
Chief Patient Supply Officer
2022-07-05
Lunger John
SOLD
-3,310.89
1.6781
-1,973
Chief Patient Supply Officer
2022-06-27
Rawcliffe Adrian
SOLD
-4,176.06
1.63
-2,562
Chief Executive Officer
2022-05-20
Wood Gavin
BOUGHT
11,325.6
0.2904
39,000
Chief Financial Officer
2022-01-18
Rawcliffe Adrian
SOLD
-35,416.2
3.1918
-11,096
Chief Executive Officer
2022-01-18
Lunger John
SOLD
-13,941.8
3.1918
-4,368
Chief Patient Supply Officer
2022-01-18
Norry Elliot
SOLD
-6,769.81
3.1918
-2,121
Chief Medical Officer
2022-01-18
Bertrand William C JR
SOLD
-13,941.8
3.1918
-4,368
Chief Operating Officer

1–10 of 50

Adrian Rawcliffe
490
Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, focuses on providing novel cell therapies primarily to patients with solid tumors in the United States and the United Kingdom. The company's specific peptide enhanced affinity receptor (SPEAR) T-cell platform enables it to identify cancer targets. It is developing ADP-A2M4 that is in phase II clinical trials with SPEARHEAD-1 for synovial sarcoma and myxoid round cell liposarcoma indications (MRCLS); in phase II clinical trials with SPEARHEAD-2 for patients with head and neck cancer; and in phase I clinical trials for urothelial, melanoma, head and neck, ovarian, non-small cell lung, esophageal and gastric, synovial sarcoma, and MRCLS cancers. The company is also developing ADP-A2AFP, which is in phase I clinical trials for hepatocellular carcinoma; and ADP-A2M4CD8, which is in phase I clinical trial for SPEAR T-cells focusing on treating patients with lung, gastroesophageal, head and neck, ovarian, and bladder cancers. It has a collaboration and license agreement with GSK; third party collaborations with Noile-Immune Biotech Inc., Alpine Immune Sciences, Inc., and National Center for Cancer Immune Therapy in Denmark; strategic alliance agreement with the MD Anderson Cancer Center; and co-development and co-commercialization agreement with Universal Cells, Inc. Adaptimmune Therapeutics plc also has a strategic collaboration and license agreement with Genentech, Inc. and F. Hoffman-La Roche Ltd to develop personalized allogeneic T-cell therapies utilizing aß T-cell receptors. Adaptimmune Therapeutics plc was founded in 2008 and is headquartered in Abingdon, the United Kingdom.

ADAP Income Statement

2022-09-30
UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)
$ in Thousands
3 Months Ended9 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Sep. 30, 2022
Sep. 30, 2021
UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS    
Revenue$ 7,007$ 1,203$ 16,120$ 4,732
Operating expenses    
Research and development(33,182)(28,211)(104,674)(81,585)
General and administrative(16,815)(15,173)(48,169)(42,529)
Total operating expenses(49,997)(43,384)(152,843)(124,114)
Operating loss(42,990)(42,181)(136,723)(119,382)
Interest income3242251,019916
Other (expense) income, net1,644(237)1,001(184)
Loss before income tax expense(41,022)(42,193)(134,703)(118,650)
Income tax expense(399)(208)(1,503)(582)
Net loss attributable to ordinary shareholders$ (41,421)$ (42,401)$ (136,206)$ (119,232)
Net loss per ordinary share    
Basic (in dollars per share)$ (0.04)$ (0.05)$ (0.14)$ (0.13)
Diluted (in dollars per share)$ (0.04)$ (0.05)$ (0.14)$ (0.13)
Weighted average shares outstanding:    
Basic (in shares)980,791,114936,600,648961,354,122933,992,708
Diluted (in shares)980,791,114936,600,648961,354,122933,992,708

ADAP Balance Sheet

2022-09-30
UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)
Sep. 30, 2022
Dec. 31, 2021
Current assets  
Cash and cash equivalents$ 79,001,000$ 149,948,000
Marketable securities - available-for-sale debt securities120,669,000219,632,000
Accounts receivable, net of allowance for doubtful accounts of $0 and $01,774,000752,000
Other current assets and prepaid expenses62,695,00045,126,000
Total current assets264,139,000415,458,000
Restricted cash1,712,0001,718,000
Operating lease right-of-use assets, net of accumulated amortization17,607,00020,875,000
Property, plant and equipment, net of accumulated depreciation of $35,229 and $36,25348,176,00030,494,000
Intangible assets, net of accumulated amortization of $4,354 and $4,051568,0001,000,000
Total assets332,202,000469,545,000
Current liabilities  
Accounts payable6,905,0008,113,000
Operating lease liabilities, current2,474,0002,320,000
Accrued expenses and other current liabilities36,079,00029,909,000
Deferred revenue, current20,622,00022,199,000
Total current liabilities66,080,00062,541,000
Operating lease liabilities, non-current19,926,00023,148,000
Deferred revenue, non-current132,233,000177,223,000
Other liabilities, non-current626,000673,000
Total liabilities218,865,000263,585,000
Stockholders' equity  
Common stock - Ordinary shares par value £0.001, 1,282,773,750 authorized and 982,719,936 issued and outstanding (2021: 1,240,853,520 authorized and 937,547,934 issued and outstanding)1,394,0001,337,000
Additional paid in capital985,312,000959,611,000
Accumulated other comprehensive income (loss)6,683,000(11,142,000)
Accumulated deficit(880,052,000)(743,846,000)
Total stockholders' equity113,337,000205,960,000
Total liabilities and stockholders' equity$ 332,202,000$ 469,545,000